Acelyrin (SLRN) Discloses CRO Errors in Izokibep Program in Wake of Investor Class Action -Hagens Berman
December 11, 2023 12:19 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Acelyrin (SLRN) Discloses CRO Errors in Izokibep Program in Wake of Investor Class Action - Hagens Berman
December 07, 2023 09:04 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
SLRN Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
December 07, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress - Hagens Berman
December 04, 2023 15:00 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
December 04, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
HAGENS BERMAN Alerts Acelyrin (SLRN) Investors to Pending Securities Fraud Class Action, Encourages Investors Who Suffered Substantial Losses to Contact Firm’s Attorneys
December 01, 2023 13:19 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
November 30, 2023 16:30 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acelyrin (SLRN) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
November 27, 2023 09:27 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate’s Progress-Hagens Berman
November 20, 2023 11:01 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress-Hagens Berman
November 16, 2023 18:42 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period:...